584 upcoming catalysts — clinical readouts, PDUFA dates, FDA decisions, and conference data cuts — ranked by importance and searchable by company, asset, or therapeutic area. 8 verified · 576 live-sourced.
584 catalysts · showing first 25
VKTX·VK2735 (oral)
Market Moving
Clinical ReadoutMetabolicPhase 3
Obesity
ExpectedQ3 2026· Confirmed
PoSⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
65%
Why It Matters
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
Verified ↗Details →VerifiedEditor-reviewed catalyst with confirmed or carefully validated timing, source context, and executive summary.
REGN·Dupixent (IL-4Rα)
Market Moving
FDA DecisionRespiratoryRegistration
COPD
ExpectedQ3 2026· Confirmed
PoSⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
80%
Why It Matters
First biologic approved for COPD would open a massive new market. Commercial peak sales estimates of $3B+ annually. Eosinophilic COPD subgroup most likely to benefit.
Verified ↗Details →VerifiedEditor-reviewed catalyst with confirmed or carefully validated timing, source context, and executive summary.
LLY·Tirzepatide
Important
Clinical ReadoutCardiovascularPhase 3
Heart Failure with Preserved EF
ExpectedH2 2026· Confirmed
PoSⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
60%
Why It Matters
HFpEF has no approved pharmacological treatments. Positive data would expand GLP-1 addressable market substantially and reinforce cardiovascular benefits beyond weight loss.
Verified ↗Details →VerifiedEditor-reviewed catalyst with confirmed or carefully validated timing, source context, and executive summary.
·BHV-7000
Important
Clinical ReadoutCNSPhase 2/Phase 3
Focal Epilepsy
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Xanamem
Important
Clinical ReadoutCNSPhase 2/Phase 3
Dementia Moderate
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Alectinib
Important
Clinical ReadoutOncologyPhase 2/Phase 3
Non-Small Cell Lung Cancer
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Alectinib - Usual
Important
Clinical ReadoutOncologyPhase 2/Phase 3
ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Abiraterone - Usual
Important
Clinical ReadoutOncologyPhase 2/Phase 3
Prostate Cancer
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·ETOPOSIDE - Usual
Important
Clinical ReadoutOncologyPhase 2/Phase 3
Small Cell Lung Cancer
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Selinexor (combination therapy)
Important
Clinical ReadoutOncologyPhase 2/Phase 3
Relapsed/Refractory Diffuse Large B-cell Lymphoma
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·FDA018-ADC
Important
Clinical ReadoutOncologyPhase 3
Triple Negative Breast Cancer
ExpectedQ3 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Avelumab
Important
Clinical ReadoutOncologyPhase 3
Solid Tumors
ExpectedQ3 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Avelumab Program Rollover Study
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·AZD9833
Important
Clinical ReadoutOncologyPhase 3
ER-Positive HER2-Negative Breast Cancer
ExpectedQ3 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·JDQ443
Important
Clinical ReadoutOncologyPhase 3
Non-Small Cell Lung Cancer
ExpectedQ3 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·HS-20093
Important
Clinical ReadoutOncologyPhase 3
Osteosarcoma
ExpectedQ3 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Trastuzumab deruxtecan
Important
Clinical ReadoutOncologyPhase 3
Gastric Cancer, Adenocarcinoma
ExpectedQ3 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·DE-117B Eye Drops
Important
Clinical ReadoutCardiovascularPhase 3
Open Angle Glaucoma
ExpectedQ3 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
56%
A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Tafasitamab
Important
Clinical ReadoutOncologyPhase 3
Diffuse Large B-cell Lymphoma
ExpectedQ3 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·zongertinib
Important
Clinical ReadoutOncologyPhase 3
Lung Cancer, Non-squamous, Non-small Cell
ExpectedQ3 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Pembrolizumab
Important
Clinical ReadoutOncologyPhase 3
Endometrial Neoplasms
ExpectedQ3 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Durvalumab
Important
Clinical ReadoutOncologyPhase 3
Non-Small Cell Lung Cancer
ExpectedQ3 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Durvalumab
Important
Clinical ReadoutOncologyPhase 3
Hepatocellular Carcinoma
ExpectedQ3 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Pemetrexed
Important
Clinical ReadoutOncologyPhase 3
Non-Small Cell Lung Cancer
ExpectedQ3 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·[O-15]-Water PET Myocardial Perfusion Imaging (MPI)
Important
Clinical ReadoutCardiovascularPhase 3
Coronary Artery Disease
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
56%
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·BL-M07D1
Important
Clinical ReadoutOncologyPhase 3
HER2-positive Breast Cancer
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
Verified: Editor-reviewed catalyst with validated timing, source context, and executive summary.
Live-Sourced: Pulled from public data sources and refreshed periodically. Timing and details should be independently verified.
PoS estimates are illustrative figures based on BIO/IQVIA phase benchmarks — not primary research. Click any catalyst to view full program details.